Taylor St Cap (@TaylorStCap) header
Taylor St Cap (@TaylorStCap) profile picture

Stocks and other musings

Joined October 2025
Photo by Taylor St Cap (@TaylorStCap)Photo by Taylor St Cap (@TaylorStCap)Photo by Taylor St Cap (@TaylorStCap)Photo by Taylor St Cap (@TaylorStCap)
Fair to say I’ve lost my edge notably this year. Every dip I’ve analyzed and passed on I should have bought. Every dip I’ve bought has kept dipping. Down week after week after week. Maybe @FDA denies best-in-disease $MLTX and maybe diabetes leader $PODD gets beat by newcomers
1
203
like $TNDM and $SENS (each of whom have 0 manufacturing know-how) and maybe $SGI never sells another mattress and maybe $CBRS is fraudulent and @CulperResearch knows more about wafer scale chip design than $AMD and $MSFT and maybe $NNBR never sells another liquid cooling system
1
215
ever again as new data center builds go to 0 … maybe. That’s how my book is priced. So there should be upside if any of that doesn’t happen. But I’ve gone from hopeful to very frustrated recently which tells me it might be time to touch grass and call it a year.
53
$MLTX: adds from Deep Track and Duquesne (Druck) ahead of catalyst rich 4Q’26 - 1H’27 $PODD: massive ($700m) buy from Sessa, who I think very highly of I’ve recently sized into both, with $MLTX as a spec biotech play and $PODD as a dislocation play that’s sold off far too much
1
300
Curious, Adam. Thoughts on your thesis after the very disappointing $ZURA data? it appears sonelokimab may have the edge after all here and is likely to be given priority review by FDA. An update to your thesis would be appreciated
Replying to @A_May_MD
Slide 5: Debunking the myth of IL17*F* Part 4 The next examples of *clinical* data that debunk the importance of hitting IL17F are the $MLTX Sonelokimab sagas. Sonelokimab was the much-hyped IL17 inhibitor developed by Moonlake Therapeutics. It was supposed to be a fast-follower to Bimzelx with “me-better” potential. Why? Sonelokimab had ~6x higher IL17FF affinity than Bimzelx! The logic here was simple: If hitting IL17F is what set Bimelx apart as the best IL17 inhibitor, then a drug that hits IL17F *even harder* would be even BETTER! Right?! Well, not only did Sonelokimab yield lower efficacy in psoriasis than Bimzelx, it even yielded lower efficacy than Taltz that doesn’t hit IL17F at all! And that isn’t even adjusting Taltz to the higher dose used in IXORA-P… Then, in HS sonelokimab actually *missed* in one of its two phase 3 trials! Now, some of this was just bad luck for sonelokimab. It is *definitely* active because it does hit IL17A quite well. However, its IL17F affinity being GREATER than its IL17A affinity may have ultimately been a *disadvantage* instead of the advantage the market thought it would be. I wonder if highly abundant IL17F actually acted as a drug sink for sonelokimab and hindered its ability to cause maximal suppression of 17A. In any case, the $MLTX/Sonelokimab case study showed us this: Maximizing IL17F affinity did NOT yield a better IL17 inhibitor…if anything, it gave us a *worse* one. This is yet another piece of clinical evidence pointing us *away* from hitting 17F and *toward* 17A, like $ZURA is going to do with Tibulizumab.
1
493
I’d recommend reading some of these patient reviews of $MLTX sonelokimab … given the data (either best in class or extremely competitive with Bimekizumab) and stellar patient reviews, it’s hard to imagine the @FDA would keep this life changing medication from patients. Powerful
1
2
429
statements like “miracle for me”, “I can’t wait for this to hit the market”, “two words - life changing”, “absolutely incredible results”, “24 hours after my injection I noticed both flares have gone down significantly”, “it actually looks promising” $MLTX
1
1
267
“it was like magic for me”, “I finally feel some relief”, “I saw much more improvement very quickly after that started” $MLTX … hard to imagine denying patients this medication … excited for a priority review decision this or next week.
2
296
I would imagine this is a contra indicator since the only other biotech I have ever bought is $AMLX … but can someone explain to me why $MLTX isn’t a $60 stock? 97% of patients with moderate+ HS don’t receive advanced therapy. They have the best molecule. Commercial launch
1
3
476
imminent with very defined upcoming catalysts including BLA acceptance in HS within the next 2 wks, phase 3 initiation of sonelokimab in PPP within 3 wks, phase 2 POLARIS in early ‘27, topline phase 3 IZAR-2 in early ‘27 … just absolutely loaded for $500m EV. No brainer $MLTX
1
170
I stand with Jensen here. His company. His vision. Shareholders love him. Employees love him. Board has no right to remove the man at the destruction of shareholder value. Put it to a vote. Typical corporate rule book does not apply here. #IStandWithJensen
4
293
✅ bottom appears to be in here. $SGI green on a bad print as the market better appreciates that they continue to take share. Falling 10yr helpful
This quoted post is unavailable.
1
365
$SGI dumping because 4Q EPS going to come in 20 cents light. Sort of a joke. Industry leader at cyclical trough embarking on synergistic verticalization and continuing to take share in a tough macro as rates fall. Couldn’t draw up a better set-up … has $ARHS written all over
1
1
649
$SGI had relentless selling all day. Who knows what that means for Monday. Stopped pretending like I have any clue these days with daily price action dominated by quants and pods. We’ll see Monday how acquisition synergies are trending … I think this trades for 12x ‘28 EPS ….
2
567
$CBRS falling knife. Wow. Some lessons learned on this one. Market was not pricing in blue wave or continued insider selling. Both were well known to all, and I had assumed both were priced in from $350 to $150, but clearly not. Where does this bottom? $50?
6
26
6,781
The good news: rotated half of this PnL into $SGI at $63 (+11%). The bad news: rotated the other half of this PnL into $CBRS at $130 (-31%). Down 10% between the 2 … since the sales: $FPS -41% / $AESI -44%. Saved myself but still getting CRUSHED on $CBRS.
Well. Sometimes it’s better to be lucky than good. Sold $FPS Monday at a weighted $38.33 and out of $AESI yesterday at a weighted $11.92 … rotated into $SGI at $63.00 and actually held in OK today despite the carnage. Can hopefully buy back at lower prices over next few wks
1
591
$CBRS has been one of the worst buys of my precessional life. Averaged in at $130, so far less pain than others … but ouch. Bags were pumped and we’ve now been deflated. Wonder what’s happening inside the brain of @GavinSBaker today
12
1
41
11,256
I just invested nearly $1.5M into Cerebras ($CBRS). My thesis? This ~$24B company has the potential to become a $250B–$1T AI giant. Here's why I believe Cerebras is one of the most undervalued opportunities in AI today. 👇
1
32
2,699
Blue wave (house + senate) + red gubernatorial victory in TX (GA at 72% Bottoms priced in) would be a boon for markets. Ends Trump’s erratic presidency while maintains DC buildout in TX. Right now markets are pricing 40% chance of moratoriums, which justifies nasty price action
1
771
Expecting more of a sell-off for AI infra into market clearing event tomorrow. Only one race matters tomorrow - TX gov. Right now markets are forced to price in a 40% chance of data center moratoriums in the most important state. Red win will lead to limit up Wednesday
1
252